S-1: Optimus Healthcare Services Files for Resale of 3,632,859 Shares of Common Stock

Optimus Healthcare Services is registering for the resale of up to 3,632,859 shares of its common stock by selling stockholders, including shares issuable upon warrant exercises.

Summary

• Optimus Healthcare Services has filed a registration statement for the potential resale of up to 3,632,859 shares of its common stock by selling stockholders.
• This includes 1,705,000 shares issuable upon the exercise of warrants and 1,927,859 shares already held by the selling stockholders.
• The shares were previously sold in two private placements completed in May 2021 and June 2022.
• The selling stockholders will sell their shares at $0.10 per share until the shares are quoted on the OTCQX, OTCQB or listed on a national securities exchange, and thereafter at market prices or negotiated prices.
• Optimus Healthcare Services will not receive any proceeds from the sale of these shares by the selling stockholders, but would receive approximately $17,000 if all warrants are exercised for cash.
• The company intends to use any proceeds from the exercise of the Warrants for working capital and other general corporate purposes.
• The company's common stock is currently quoted on the Pink Open Market under the symbol OHCS, with a closing price of $0.0855 on June 25, 2024.
• The company has three classes of stock outstanding: common stock, Series A preferred stock, and Series B preferred stock, all entitled to one vote per share.
• The company's executive officers and directors beneficially own approximately 5.1% of the outstanding voting power, while majority shareholders control approximately 41.4%.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are some positive aspects, such as the potential for warrant exercises to generate cash, the overall sentiment is negative due to the company's history of operating losses, need for additional funding, and going concern uncertainty.

Positives

• The company could receive approximately $17,000 if all warrants are exercised for cash, which would be used for working capital and general corporate purposes.
• The company's executive officers and directors beneficially own approximately 5.1% of the outstanding voting power, while majority shareholders control approximately 41.4%.

Negatives

• Optimus Healthcare Services will not receive any proceeds from the sale of shares by the selling stockholders.
• The company's common stock is currently quoted on the Pink Open Market, which may indicate limited liquidity and higher volatility.
• The company has a history of operating losses and may need additional funding in the near future.
• The company's majority shareholders control approximately 41.4% of the outstanding voting power, which could limit the influence of other shareholders.

Risks

• The company will need additional funding in the near future to continue its current level of operations and growth.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's limited operating history may make it difficult to evaluate the success of its business to date and to assess its future viability.
• The company is a holding company and its only material assets are cash in hand, accounts receivables and equity interests in its operating subsidiaries.
• The company has experienced significant historical, and may experience significant future, operating losses, and net losses, which may hinder its ability to meet working capital requirements or service its indebtedness.
• The company's current sources of funding are limited, and any additional funding that it may obtain may be on unfavorable terms and may significantly dilute its existing shareholders.
• The majority of the company's customers contracts can be terminated, delayed or reduced in scope upon short notice or no notice.
• The company's business and growth strategy depend on its ability to maintain and expand its network of established, board-certified physicians, hospitals, and other provider specialists.
• An active trading market for the company's common stock may not develop, and you may not be able to sell your common stock at or above the initial public offering price.
• The company depends on its key personnel to manage its business effectively in a rapidly changing market.
• The company's majority shareholders, executive officers and directors beneficially own approximately 52.6% of the outstanding voting power of the Company.
• There has been a limited public market for the company's common stock, and we do not know whether one will develop to provide you adequate liquidity.
• Because the company's common stock may be deemed a low-priced penny stock, an investment in our common stock should be considered high-risk and subject to marketability restrictions.
• The company does not currently or for the foreseeable future intend to pay dividends on its common stock.
• The company became subject to the reporting requirements with the Securities and Exchange Commission in July 2022. Until such time as we satisfy the requirements under Rule 144(i), there may not be liquidity in our common stock.

Future Outlook

The company anticipates incurring additional losses until such time, if ever, that it can generate significant sales or revenue from its services. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans for the Companys operating businesses provide the opportunity for the Company to continue as a going concern.

Industry Context

The company operates in the clinical research industry, which is fragmented and competitive. The company faces competition from small, niche service providers, medium-sized providers, and large CROs.

Related Party Transactions

• On January 28, 2022, the Company entered into a stock purchase agreement with Workers Health Rx, Inc. (Vitality Rx) and Marc Wiener, the sole shareholder, who was also our President, pursuant to which we acquired 100% of the outstanding equity interests of Vitality Rx in exchange for the issuance of 250,000 shares of our common stock and $350,000.
• On May 5, 2023, the Company entered into an agreement with Marc Weiner where he agreed to return 250,000 shares of common stock in exchange for $136,827 to help offset the cost of a pharmacy initiative to allow it to move forward with its strategic plan.
• Subsequent to December 31, 2023, the Company received a non interest bearing bridge loan from KORR in the total amount of $270,000, subject to the terms of the June 4, 2024 amendment with Arena Investors, LP.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional shares of common stock or preferred stock in the future.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan.
• The company's executive officers and directors beneficially own approximately 5.1% of the outstanding voting power of the Company. Our majority shareholders control approximately 41.4% of the outstanding voting power of the Company. As a result, they will be able to exercise significant influence over all matters requiring shareholder approval.

Next Steps

• The company will use commercially reasonable best efforts to consummate a sale of some or all of the assets of its CRA business, a sale of some or all of the equity interests of the CRA business, or a merger of the CRA business, in each case, to an independent, non-affiliated third party in an arms length transaction, subject to satisfaction of certain milestones.
• The company will use commercially reasonable best efforts to consummate an equity financing that results in gross proceeds of at least $2,000,000 to the Company on or prior to February 28, 2025, subject to consent of the Purchasers, which consent will not be unreasonably withheld (a Qualified Subsequent Financing).

Key Dates

Keywords

common stock, selling stockholders, warrants, resale, Optimus Healthcare Services, OHCS, private placement, clinical trials, healthcare